Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ostrovskyy (Ivano-Frankivsk, Ukraine), I. Savelikhina (Ivano-Frankivsk, Ukraine), K. Ostrovska (Ivano-Frankivsk, Ukraine), O. Varunkiv (Ivano-Frankivsk, Ukraine), G. Korzh (Ivano-Frankivsk, Ukraine), M. Kulynych-Miskiv (Ivano-Frankivsk, Ukraine), K. Shvets (Ivano-Frankivsk, Ukraine), N. Korzh (Ivano-Frankivsk, Ukraine). C-reactive protein and the type IV collagen measurementin severe COPD: Value of roflumilast. 556

Member's Comments

No comment yet.

Related content which might interest you: The influence of roflumilast on the IV-type collagen level in patients with III stage COPD Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012 Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Source: Eur Respir J 2008; 32: 1451-1457 Year: 2008 Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 A neo-epitope of collagen type VII (C7) is elevated in serum of patients with COPD and SSC Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Matrix metalloproteinase, hyaluronic acid and C-reactive protein: Are they really markers of lung obstruction at COPD but not cardiovascular comorbidity? Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Parameters of sIgE and sIgG4-autoAbs to lung elastin, collagen type III and myosin in bronchial asthma in association with chronic infection. Source: International Congress 2019 – Understanding the mechanisms underlying airway diseases Year: 2019 Collagen degradation profile in serum of patients with COPD or IPF Source: Annual Congress 2012 - Monitoring of airway diseases: far from the airways Year: 2012 Serum type III procollagen peptide in idiopathic pulmonary fibrosis: peptide levels and anti-fibrosis therapy Source: Eur Respir J 2005; 26: Suppl. 49, 30s Year: 2005 The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Polymorphisms in the type IV collagen alpha3 gene and the risk of COPD Source: Eur Respir J 2008; 32: 35-41 Year: 2008 Changes of urotensin II in induced sputum and plasma of patients with COPD and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 672s Year: 2006 Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Source: Eur Respir J 2006; 27: 902-907 Year: 2006 A novel serum biomarker of type XXVIII collagen turnover is elevated in lung cancer but not in COPD Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 COPD, asthma and C-reactive protein Source: Eur Respir J 2006; 27: 874-876 Year: 2006 Dynamics of marker of inflammation - sICAM-1 in the process of treatment of COPD GOLD III destabilization phase in overweight patients. Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease Year: 2021 Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014